Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press10810.17650/1726-9776-2011-7-1-73-78DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряUSE OF FLUORESCENCE IN SITU HYBRIDIZATION ASSAY ON URINE SEDIMENT CELLS TO DIAGNOSE URINARY BLADDER CANCER AND ITS RECURRENCESYПРИМЕНЕНИЕ МЕТОДА ФЛУОРЕСЦЕНТНОЙ ГИБРИДИЗАЦИИ IN SITU НА КЛЕТКАХ ОСАДКА МОЧИ ДЛЯ ДИАГНОСТИКИ РАКА МОЧЕВОГО ПУЗЫРЯ И ЕГО РЕЦИДИВОВVorobtsovaI. E.ВоробцоваИ. Е.
Russian Federation
d-tim@mail.ruVasilyevaZ. Zh.ВасильеваЗ. Ж.
Russian Federation
d-tim@mail.ruShkolnikM. I.ШкольникМ. И.
Russian Federation
d-tim@mail.ruTimofeevD. A.ТимофеевД. А.
Russian Federation
d-tim@mail.ruOdintsovaM. V.ОдинцоваМ. В.
Russian Federation
d-tim@mail.ruGappoevM. U.ГаппоевМ. У.
Russian Federation
d-tim@mail.ruUrbanskiyA. I.УрбанскийА. И.
Russian Federation
d-tim@mail.ruKarelinM. I.КарелинМ. И.
Russian Federation
d-tim@mail.ruRussian Research Center for Radiology and Surgical Technologies, Saint PetersburgНациональный центр онкологии, Баку, Азербайджанская РеспубликаНациональный центр онкологии, Баку, Азербайджанская Республика300320117173782707201427072014https://oncourology.abvpress.ru/oncur/article/view/108

Fluorescence in situ hybridization (FISH) assay was used to detect tumor cells in the urine sediment of patients diagnosed as having urinary bladder cancer (UBC). For this, the investigators applied a fluorescence DNA probe kit (UroVysion) that could reveal the cytogenetic abnormalities characteristic for UBC, such as hyperploidy for chromosomes 3, 7, and 17 and deletion of the 9p21 locus, in the cast-off cells. Twenty-eight patients with the primary diagnosis of UBC, 12 with its suspected recurrence, 3 subjects without UBC were examined. The findings were compared with cystoscopic data after urine samples were taken. The sensitivity of the UroVysion test totaled 78.5 ± 9.7 % for all stages of primary cancer (pT1-pT4), 87.5 ± 11.6 % for its early stage (рТ1), and 100 % for UBC recurrences. Hyperploidy was a predominant type of cytogenetic abnormalities in the cast-off tumor cells. Among the abnormal cells, the types of hyperploidy (tri-, tetrasomy) were most common for chromosome 3 and less for chromosome 7. Thus, the UroVysion test is a noninvasive highly sensitive tool that may be used in clinical practice to improve the diagnosis of UBC, to detect recurrences, and to monitor the efficiency of treatment.

urinary bladder cancerfluorescence in situ hybridization assaydiagnosis of urinary bladder cancerрак мочевого пузыряметод флуоресцентной гибридизации in situдиагностика рака мочевого пузыря1. Schmidbauer J., Witjes F., Schmeller N. et al. Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135–8.Schmidbauer J., Witjes F., Schmeller N. et al. Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135–8.2. Grossman H.B., Messing E., Soloway M. et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293(7):810–6.Grossman H.B., Messing E., Soloway M. et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293(7):810–6.3. Kallioniemi A., Kallioniemi O.P., Citro G. et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Gen Chromosom Cancer 1995;12(3):213–9.Kallioniemi A., Kallioniemi O.P., Citro G. et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Gen Chromosom Cancer 1995;12(3):213–9.4. Mao L., Schoenberg M.P., Scicchitano M. et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271(5249):659–62.Mao L., Schoenberg M.P., Scicchitano M. et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271(5249):659–62.5. Боженко В.К., Кулинич Т.М., Мельникова Н.В., Нестеров П.В. Проточная цитометрия осадка мочи в диагностике рака мочевого пузыря. Вопр онкол 2007;53:468–72.Боженко В.К., Кулинич Т.М., Мельникова Н.В., Нестеров П.В. Проточная цитометрия осадка мочи в диагностике рака мочевого пузыря. Вопр онкол 2007;53:468–72.6. Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116–23.Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116–23.7. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3(4):507–19.Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3(4):507–19.8. Skacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169(6):2101–5.Skacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169(6):2101–5.9. Sarosdy M.F., Schellhammer P., Bokinsky G. et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168(5):1950–4.Sarosdy M.F., Schellhammer P., Bokinsky G. et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168(5):1950–4.10. Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116(1):79–86.Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116(1):79–86.11. Yoder B.J., Skacel M., Hedgepeth R. et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295–301.Yoder B.J., Skacel M., Hedgepeth R. et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295–301.12. Richter J., Jiang F., Gorog J.P. et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860–4.Richter J., Jiang F., Gorog J.P. et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860–4.13. Севанькаев А.В., Лушников Е.Ф., Карякин О.Б. и др. Клиническое применение FISH-метода в ранней диагностике поверхностного рака мочевого пузыря. Онкоурология 2008;(4):61–5.Севанькаев А.В., Лушников Е.Ф., Карякин О.Б. и др. Клиническое применение FISH-метода в ранней диагностике поверхностного рака мочевого пузыря. Онкоурология 2008;(4):61–5.